Clinical trials: Hematologic
Sickle Cell Disease, Hyperbaric Oxygen Therapy
Hyperbaric-oxygen Therapy (HBOT) Versus Placebo for Treating Vaso-Occlusive Crisis (VOC) in Sickle Cell Disease (SCD)
This is a randomised, controlled, double-blind, placebo trial of HBOT (intervention) superiority in the treatment of VOC in SCD, to demonstrate the effectiveness of HBOT for the decrease in pain level in the treatment of SCD-VOC.
- Conditions
- Sickle Cell Disease, Hyperbaric Oxygen Therapy, Vaso-occlusive Crisis
- Trial name
- HBOT-SCD (NCT05289700)
- Testing
- HBOT in Hyperbaric chamber
- Where
- 3 sites in France, Switzerland
- Volunteers
- 100 people
- Sponsor
- University Hospital, Geneva
Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse
Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML
The goal of this research study is to test if the combination of a new T cell therapy (dendritic cell (DC) / acute myeloid leukemia (AML) primed T cells), vaccine (DC/AML fusion vaccine) and standard of care decitabine and…
- Trial name
- NCT07374029
- Testing
- DC/AML Fusion Vaccine, T-Cell Therapy, Decitabine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- David Avigan
Beta Thalassaemia
Long-term Follow-up of Subjects Treated With OTL-300 for Transfusion Dependent Beta-thalassemia Study (TIGET-BTHAL)
OTL-300 is a gene therapy drug product consisting of autologous hematopoietic stem/progenitor cluster of differentiation (CD) 34+ cells genetically modified with a lentiviral vector (GLOBE) encoding the human beta globin gene.
- Trial name
- NCT03275051
- Testing
- Safety and Efficacy assessments
- Where
- Italy
- Volunteers
- 9 people
- Sponsor
- IRCCS San Raffaele
Polycythemia Vera
Clinical and Laboratory Characteristics of Polycythemia Vera
The study is observational, longitudinal, retrospective and prospective, on patients with PV. Patients with PV diagnosed from 2000 to 2023 according to WHO2017 criteria will be considered.
- Trial name
- PV-ARC (NCT06134102)
- Where
- 22 sites in Italy
- Volunteers
- 1,150 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
B Cell Lymphoma, Multiple Myeloma
A Clinical Study of Allogeneic CD19/BCMA CAR-T Cells for the Treatment of R/R B-cell Malignant Tumors
A single arm, open-label pilot study is designed to determine the safety and efficacy of CD19 and B-cell maturation antigen (BCMA) targeted allogenic CAR-T cells (RN1101) in patients with relapsed/refractory B-cell or plasma…
- Trial name
- NCT06976437
- Testing
- RN1101 injection
- Where
- China
- Volunteers
- 21 people
- Sponsor
- YANRU WANG
Pediatric Patients, Hematologic Malignancy
TCR Alpha/Beta and CD19-deplete Haplo-HSCT
This is an open label, interventional, non-randomized, phase II trial of TCR alpha/beta and CD19-depeleted allogeneic HCT in pediatric patients with hematologic disease.
- Conditions
- Pediatric Patients, Hematologic Malignancy, Other Hematologic Condition
- Trial name
- NCT05288595
- Testing
- CliniMACS Plus Instrument
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Hemophilia
A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia
This is a multicenter, multinational, open-label, one-way cross-over, Phase 3, single-arm study for treatment of hemophilia. The purpose of this study is to measure the frequency of treated bleeding episodes with fitusiran in…
- Trial name
- ATLAS-NEO (NCT05662319)
- Testing
- Fitusiran, Clotting factor concentrates (CFC) or bypassing agents (BPA), Antithrombin concentrate (ATIIIC)
- Where
- 50 sites in United States, Canada and 15 more
- Volunteers
- 91 people
- Sponsor
- Sanofi
Myelodysplastic Syndromes
Azacitidine and Erythropoietin Versus Azacitidine Alone for Patients With Low-Risk Myelodysplastic Syndromes
This trial is designed to explore a modified dose and schedule of azacitidine in order to more effectively address the needs of patients with low-risk myelodysplastic syndromes (MDS), i.e., to alter the natural history of the…
- Trial name
- NCT00379912
- Testing
- Azacitidine, Erythropoietin, Azacitidine (Monotherapy)
- Where
- 9 sites in United States
- Volunteers
- 15 people
- Sponsor
- Larry Cripe, MD
Sickle Cell Disease, Executive Dysfunction
Methylphenidate to Address Attention and Executive Deficits Among Children With Sickle Cell Disease
The purpose of this study is to determine if patients with sickle cell disease (SCD) can consistently take a drug called Methylphenidate (MPH) daily, once a day for 4 weeks to help with any thinking, attention or schoolwork…
- Conditions
- Sickle Cell Disease, Executive Dysfunction, Cognitive Impairment, Attention Deficit/Hyperactivity Disorder (ADHD)
- Trial name
- NCT07226219
- Testing
- Extended-Release Methylphenidate
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- St. Jude Children's Research Hospital
Non-Hodgkin's Lymphoma, Hodgkin's Disease
Immune Mobilization of Autologous Peripheral Blood Stem Cells Using Interleukin-2 and GM-CSF
We postulate that the combination of IL-2 and GM-CSF immunotherapy will efficiently mobilize autologous peripheral blood stem cells and activated immune effector cells in patients with a hematologic malignancy.
- Conditions
- Non-Hodgkin's Lymphoma, Hodgkin's Disease, Multiple Myeloma, Other Plasma Cell Dyscrasia (Waldenstrom, Amyloidosis)
- Trial name
- NCT00952237
- Testing
- GM-CSF, IL-2
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Multiple Myeloma
A Study of Granix to Disrupt the Bone Marrow Microenvironment in Patients With Multiple Myeloma Undergoing Autologous Transplantation
This randomized phase II trial compares how well adding XMO2 Filgrastim (Granix) to melphalan before a stem cell transplant works in treating patients with multiple myeloma.
- Trial name
- NCT02112045
- Testing
- Granix, High dose melphalan (HDR), Autologous Stem Cell Transplant (ASCT)
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Washington University School of Medicine
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Chronic Graft-versus-host Disease (cGvHD) Prophylaxis With or Without ATG Prior to Stem Cell Transplantation (SCT) From HLA-identical Siblings in Patients With Acute Leukemia
This multicenter, prospective phase III-study is to compare the administration of ATG FRESENIUS to the NON-administration of ATG FRESENIUS in a myeloablative conditioning regimen followed by allogeneic hematopoeitic stem cell…
- Trial name
- NCT00678275
- Testing
- ATG FRESENIUS (Anti-Lymphocyte-Globulin)
- Where
- Germany
- Volunteers
- 161 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Acute Myeloid Leukemia
A Study of Ficlatuzumab With HiDAC and HiDAC Alone in Adults With Relapsed or Refractory Acute Myeloid Leukemia
This is a Phase 2, randomized, open-label, multicenter study to evaluate the safety and efficacy of ficlatuzumab in combination with high-dose cytarabine (HiDAC) and HiDAC alone in subjects with relapsed or refractory acute…
- Trial name
- CyFi2 (NCT04100330)
- Testing
- Ficlatuzumab, Cytarabine
- Sponsor
- AVEO Pharmaceuticals, Inc.
Telangiectasia, Hereditary Hemorrhagic, Epistaxis
North American Study of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)
The purpose of the NOSE Study is to carefully examine the efficacy and safety of 3 nasal sprays (bevacizumab, estriol, and tranexamic acid), compared to placebo, for the treatment of HHT related nosebleeds.
- Trial name
- NOSE (NCT01408030)
- Testing
- Sterile saline, Bevacizumab, Estriol
- Where
- 6 sites in United States
- Volunteers
- 123 people
- Sponsor
- James Gossage
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCT
This Research study is being done to characterize the safety, tolerability, and preliminary antitumor activity of the NEXI-001 T cell product (a new experimental therapy), which contains populations of CD8+ T cells targeting…
- Trial name
- NCT04284228
- Testing
- Infusion of NEXI-001 T Cells
- Where
- 5 sites in United States
- Volunteers
- 22 people
- Sponsor
- NexImmune Inc.
Indolent Non-Hodgkin Lymphomas/Chronic Lymphocytic Leukemia
Blinatumomab Expanded T-cells (BET) in Indolent Non-Hodgkin Lymphomas/Chronic Lymphocytic Leukemia
Non-Hodgkin CD20 + Indolent Lymphoma (iNHL) and Chronic Lymphatic Leukemia (CLL) are the most frequent neoplasms of B lymphocytes.
- Trial name
- BET2017 (NCT03823365)
- Testing
- Blinatumomab Expanded T-cells (BET)
- Where
- Italy
- Volunteers
- 19 people
- Sponsor
- A.O. Ospedale Papa Giovanni XXIII
Brain and Central Nervous System Tumors, Drug/Agent Toxicity by Tissue/Organ
Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen
RATIONALE: Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Drug/Agent Toxicity by Tissue/Organ, Lymphoma, Thrombocytopenia
- Trial name
- NCT00074165
- Testing
- Rituxan, Cyclophosphamide, Etoposide
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- OHSU Knight Cancer Institute
Fallopian Tube Carcinoma, Infectious Disorder
Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, Primary Peritoneal, or Carcinosarcoma Cancer
This phase I trial is studying the side effects of giving carboplatin and paclitaxel together with pegfilgrastim in treating patients with stage III or stage IV ovarian epithelial, fallopian tube, primary peritoneal, or…
- Conditions
- Fallopian Tube Carcinoma, Infectious Disorder, Neutropenia, Ovarian Carcinosarcoma
- Trial name
- NCT00352300
- Testing
- Adjuvant Therapy, Carboplatin, Paclitaxel
- Where
- 11 sites in United States
- Volunteers
- 43 people
- Sponsor
- Gynecologic Oncology Group
Immune Thrombocytopenia (ITP)
V-IMMUNE® for Immune Thrombocytopenia
This is a multicenter, prospective clinical trial evaluating the efficacy and safety of V-IMMUNE®, a 5% human normal immunoglobulin formulation administered intravenously, for the treatment of immune thrombocytopenia (ITP) in…
- Trial name
- TIP (NCT06962631)
- Testing
- 5% (5g/100 ml) intravenous immunoglobin
- Where
- 2 sites in Brazil
- Volunteers
- 31 people
- Sponsor
- On Pharma Importadora, Exportadora e Distribuidora de Medicamentos LTDA.
Thrombotic Microangiopathy, Acute Kidney Injury
French National Cohort MATRIX "Renal and Systemic Thrombotic Microangiopathy"
Thrombotic microangiopathies (TMAs) are a diverse, rare but serious group of diseases. Progress has been made regarding the epidemiology of TMA (Bayer CJASN 2019).
- Conditions
- Thrombotic Microangiopathy, Acute Kidney Injury, Hemolytic Uremic Syndrome, Nephrology
- Trial name
- MATRIX (NCT05991245)
- Testing
- Collecting datas
- Where
- France
- Volunteers
- 1,000 people
- Sponsor
- University Hospital, Tours
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.